Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus.

ABSTRACT:

Objective

We evaluated the effects of the B-cell activating factor (BAFF)-targeting antibody Belimumab on human nonmemory B-cell pools. Human B-cell pools were identified using surface markers adapted from mouse studies that specifically assessed reductions in immature B cells due to BAFF depletion. Patients with systemic lupus erythematosus (SLE) have high levels of both BAFF and immature B cells. Mechanistic mouse studies provide a framework for understanding human responses to therapies that target B cells.

Methods

Peripheral blood mononuclear cells were isolated from healthy donors and SLE patients on Belimumab or standard-of-care therapy (SCT). Cells were stained for flow cytometry to identify B-cell subsets based on CD21/CD24. Differences in subset proportions were det

SUBMITTER: Benitez A 

PROVIDER: S-EPMC7769209 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature